Rhamnetin improves antioxidant status in the liver of Ehrlich solid tumor bearing mice

Mustafa Nisari,Özlem Bozkurt,Tolga Ertekin,Dilek Ceylan,Neriman İnanç,Özge Al,Hatice Güler,Erdoğan Unur
DOI: https://doi.org/10.36472/msd.v7i5.380
2020-05-21
Medical Science and Discovery
Abstract:Objective: Rhamnetin, a flavanol, is in the subclasses of the flavonoids existing in plants. The antioxidant properties of several plants containing flavonoids have been extensively studied in several diseases including cancer. This study investigated the effects of rhamnetin on tumor masses, oxidant and antioxidant status in the livers of mice bearing Ehrlich solid tumor. Material and Methods: Fifty male Balb/C mice weighing 25-30 g were used in the study. Ten mice were kept for Ehrlich ascites tumor (EAT) cells production and the remaining mice were randomly assigned to four groups containing 10 mice in each as healthy control and treatments receiving 1x106 EAT cells and EAT cells plus 100 μg/kg/day or 200 μg/kg/day rhamnetin via subcutaneous route. The tumor inhibition rates of rhamnetin treatments were calculated. The livers were analyzed for malondialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT) levels. Results: Compare to tumor control, both levels of rhamnetin suppressed tumor masses throughout the experiment. The MDA levels were increased whereas SOD and CAT activities were reduced by EAT cells injection in the liver of mice. The 100 μg/kg/day rhamnetin treatment decreased MDA level but 200 μg/kg/day rhamnetin had no significant effect on increased MDA level. The reduced liver SOD (p<0.001) and CAT (p<0.01) activities were elevated by both levels of rhamnetin injection. Conclusions: The results of this study have revealed that rhamnetin suppresses tumor progression and improves antioxidant status in the livers of solid tumor-bearing mice.
What problem does this paper attempt to address?